About Altanova

Michael W. Porter

More than twenty-five years building, acquiring and scaling regulated healthcare and specialty pharmaceutical platforms across the United States, Europe and international markets. Michael W. Porter is Founder and Executive Chairman of Altanova Pharma Group AG in Zug, Switzerland, where he leads corporate strategy, governance, platform architecture and strategic partnerships. He co-founded Covis Pharma Group and served as its Chief Executive Officer, building the company into a top-ten global respiratory pharmaceutical platform with more than US$600 million in annual sales, more than 300 employees and commercial operations across more than 55 countries, while completing 23 M&A transactions. The Covis platform generated more than US$1.5 billion in distributed profit for its institutional sponsors across three monetization events. Across his career, he has led more than 25 life-sciences M&A and strategic transactions. Michael is Co-Founder and Managing Partner of PG Equity Group, the family office through which he and Liliana Gómez invest as operating partners in regulated healthcare, technology and critical-minerals businesses. He also serves as Independent Director and Audit Committee Chair of Freedom Metals Acquisition Corp., a Nasdaq-listed company, and as a director of restor3d, Pressio Spine and Huxley Medical, including Audit Committee Chair responsibilities at restor3d and Pressio Spine. He holds an MBA from Columbia Business School with a concentration in Finance and International Business.

Dr. Raghav Chari

Thirty years in biopharmaceutical research, development and commercialisation across neurology, oncology, inflammation, metabolic disease and dermatology. Dr. Raghav Chari advises Altanova on portfolio selection, formulation strategy and development planning. He currently serves as Chief Science Officer of Azurity Pharmaceuticals, where he is responsible for scientific strategy and development of the company's clinical pipeline. He previously served as Chief Innovation Officer of Covis Pharma, where he led research and development, and held senior leadership roles at Dr. Reddy's Laboratories and Promius Pharma. His expertise centres on 505(b)(2) and hybrid-medicine development, integrating formulation science, modelling, clinical pharmacology and late-stage development. Raghav began his career at McKinsey & Company, advising biopharmaceutical clients on strategy, licensing and M&A. He has contributed to more than 50 licensing, product-development and corporate transactions and has co-founded biotechnology companies working at the intersection of drug discovery and artificial intelligence. He holds a PhD in Physics from Princeton University and a BSc in Mathematics from the California Institute of Technology.

Nick Kelly

More than twenty years in end-to-end global pharmaceutical supply-chain leadership across branded, generic and medical-device organisations, including as Chief Supply Chain Officer. Nick Kelly advises Altanova on supply-network design, supplier strategy, technical-operations readiness and operational resilience. He is Chief Supply Chain Officer of Adalvo, a global B2B pharmaceutical company supporting more than 170 partners across 140 markets. Nick previously served as Senior Vice President, Supply Chain at Covis Pharma, where he worked alongside Michael Porter for eight years and led end-to-end global supply-chain operations through M&A integrations, portfolio expansion and digital-transformation programmes. Earlier in his career, he held senior regional and global supply-chain roles at Cardinal Health, Teva Pharmaceuticals and Johnson & Johnson. His experience spans demand planning, procurement, logistics and customer service, with particular depth in supplier relationships, contract negotiation, sustainable sourcing and supply-chain risk management.